Abstract
Kozva Co Ltd, under license from Roche Holding AG, is developing K-111, an orally available peroxisome proliferator-activated receptor a ligand and insulin-potentiating agent, for the potential treatment of type 2 diabetes. Phase II clinical trials of K-111 are underway.
MeSH terms
-
Animals
-
Clinical Trials, Phase II as Topic
-
Diabetes Mellitus, Type 2 / drug therapy
-
Drug Evaluation / methods*
-
Drug Evaluation, Preclinical / methods
-
Humans
-
Hypoglycemic Agents / pharmacology
-
Hypoglycemic Agents / therapeutic use
-
Insulin / pharmacology
-
Insulin / therapeutic use*
-
Lauric Acids / pharmacology
-
Lauric Acids / therapeutic use*
-
PPAR alpha / agonists*
Substances
-
2,2-dichloro-12-(p-chlorophenyl)-dodecanoic acid
-
Hypoglycemic Agents
-
Insulin
-
Lauric Acids
-
PPAR alpha